Common Stocks - 97.1%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 88.2%
|
|||
Biotechnology - 88.2%
|
|||
4D Molecular Therapeutics, Inc. (a)
|
197,868
|
1,501,818
|
|
AbbVie, Inc.
|
3,625,003
|
534,216,683
|
|
ACADIA Pharmaceuticals, Inc. (a)
|
350,800
|
5,665,420
|
|
Adagio Therapeutics, Inc.
|
326,216
|
965,599
|
|
ADC Therapeutics SA (a)(b)
|
755,238
|
5,165,828
|
|
Adicet Bio, Inc. (a)
|
788,129
|
9,315,685
|
|
Adverum Biotechnologies, Inc. (a)(c)
|
10,597,366
|
9,507,957
|
|
Aerovate Therapeutics, Inc. (b)
|
201,551
|
2,448,845
|
|
Agios Pharmaceuticals, Inc. (a)
|
235,571
|
4,586,567
|
|
Akouos, Inc. (a)(b)
|
1,103,186
|
3,441,940
|
|
Alector, Inc. (a)
|
914,318
|
8,100,857
|
|
Alkermes PLC (a)
|
710,936
|
21,221,440
|
|
Allena Pharmaceuticals, Inc. (a)(b)
|
106,183
|
12,530
|
|
Allogene Therapeutics, Inc. (a)(b)
|
1,122,870
|
8,904,359
|
|
Allovir, Inc. (a)(b)
|
944,668
|
3,655,865
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
1,270,039
|
159,770,906
|
|
ALX Oncology Holdings, Inc. (a)
|
600,204
|
4,603,565
|
|
Ambrx Biopharma, Inc. ADR
|
1,361,508
|
5,350,726
|
|
Amgen, Inc.
|
5,590
|
1,435,177
|
|
Amicus Therapeutics, Inc. (a)
|
1,364,901
|
10,400,546
|
|
AnaptysBio, Inc. (a)(b)
|
192,196
|
3,649,802
|
|
Apellis Pharmaceuticals, Inc. (a)
|
1,363,284
|
56,508,122
|
|
Applied Therapeutics, Inc. (a)(b)
|
595,436
|
857,428
|
|
Arcturus Therapeutics Holdings, Inc. (a)(b)
|
920,424
|
18,298,029
|
|
Arcus Biosciences, Inc. (a)(b)
|
3,193,396
|
60,514,854
|
|
Arcutis Biotherapeutics, Inc. (a)
|
868,174
|
18,127,473
|
|
Argenx SE ADR (a)
|
456,947
|
141,333,707
|
|
Arrowhead Pharmaceuticals, Inc. (a)
|
2,258,670
|
75,349,231
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
659,409
|
55,726,655
|
|
Atara Biotherapeutics, Inc. (a)
|
684,540
|
3,559,608
|
|
aTyr Pharma, Inc. (a)(b)
|
1,146,952
|
3,222,935
|
|
Aura Biosciences, Inc. (b)
|
603,459
|
10,542,429
|
|
Aurinia Pharmaceuticals, Inc. (a)(b)
|
463,686
|
5,230,378
|
|
Autolus Therapeutics PLC ADR (a)(b)
|
380,185
|
1,041,707
|
|
Avidity Biosciences, Inc. (a)(b)
|
279,484
|
3,893,212
|
|
Axcella Health, Inc. (a)(b)
|
1,051,598
|
2,229,388
|
|
Beam Therapeutics, Inc. (a)(b)
|
220,992
|
7,774,499
|
|
BELLUS Health, Inc. (a)
|
1,580,683
|
12,550,623
|
|
Bicycle Therapeutics PLC ADR (a)(b)
|
498,347
|
7,968,569
|
|
BioAtla, Inc. (a)(b)
|
313,190
|
754,788
|
|
BioCryst Pharmaceuticals, Inc. (a)(b)
|
4,192,205
|
39,029,429
|
|
Biogen, Inc. (a)
|
299,116
|
59,823,200
|
|
BioMarin Pharmaceutical, Inc. (a)
|
439,436
|
33,014,827
|
|
Biomea Fusion, Inc. (a)(b)
|
960,229
|
5,271,657
|
|
BioNTech SE ADR (a)
|
195,228
|
31,892,446
|
|
BioXcel Therapeutics, Inc. (a)(b)
|
351,727
|
4,115,206
|
|
Blueprint Medicines Corp. (a)
|
957,262
|
52,649,410
|
|
BridgeBio Pharma, Inc. (a)(b)
|
893,742
|
6,104,258
|
|
Candel Therapeutics, Inc. (b)
|
901,800
|
3,399,786
|
|
Celldex Therapeutics, Inc. (a)
|
849,200
|
19,973,184
|
|
Centessa Pharmaceuticals PLC ADR
|
10,300
|
46,350
|
|
Century Therapeutics, Inc.
|
834,618
|
7,252,830
|
|
Cerevel Therapeutics Holdings (a)(b)
|
1,100,980
|
28,768,607
|
|
ChemoCentryx, Inc. (a)
|
1,819,622
|
40,522,982
|
|
Chinook Therapeutics, Inc. (a)
|
352,081
|
5,344,590
|
|
Chinook Therapeutics, Inc. rights (a)(d)
|
115,821
|
5,791
|
|
Codiak Biosciences, Inc. (a)(b)
|
402,539
|
1,123,084
|
|
Cogent Biosciences, Inc. (a)
|
411,536
|
1,897,181
|
|
Compass Therapeutics, Inc.
|
2,750,000
|
8,387,500
|
|
ContraFect Corp. (a)(b)
|
456,309
|
1,551,451
|
|
Crinetics Pharmaceuticals, Inc. (a)
|
2,123,187
|
35,563,382
|
|
CRISPR Therapeutics AG (a)(b)
|
297,822
|
17,288,567
|
|
Cullinan Oncology, Inc. (a)(b)
|
124,940
|
1,335,609
|
|
Cyclerion Therapeutics, Inc. (a)
|
837,285
|
521,294
|
|
Cyclerion Therapeutics, Inc. (a)(e)
|
94,809
|
59,028
|
|
Cyteir Therapeutics, Inc.
|
670,923
|
1,274,754
|
|
Cytokinetics, Inc. (a)(b)
|
2,338,471
|
93,304,993
|
|
Day One Biopharmaceuticals, Inc. (a)(b)
|
1,270,082
|
7,899,910
|
|
Denali Therapeutics, Inc. (a)
|
664,751
|
16,146,802
|
|
Design Therapeutics, Inc. (a)(b)
|
1,024,935
|
12,791,189
|
|
Dyne Therapeutics, Inc. (a)
|
72,200
|
347,282
|
|
Enanta Pharmaceuticals, Inc. (a)
|
349,846
|
13,969,351
|
|
Entrada Therapeutics, Inc. (b)
|
944,780
|
6,386,713
|
|
Epizyme, Inc. (a)
|
2,621,335
|
1,100,961
|
|
EQRx, Inc. (a)(b)
|
507,567
|
2,822,073
|
|
EQRx, Inc.:
|
|||
rights (a)(d)
|
116,649
|
311,453
|
|
rights (a)(d)
|
49,993
|
105,485
|
|
Erasca, Inc.
|
810,023
|
4,390,325
|
|
Evelo Biosciences, Inc. (a)(b)
|
1,098,999
|
2,307,898
|
|
Exelixis, Inc. (a)
|
3,178,634
|
58,264,361
|
|
Fate Therapeutics, Inc. (a)(b)
|
733,387
|
16,941,240
|
|
Foghorn Therapeutics, Inc. (a)(b)
|
544,119
|
7,019,135
|
|
Forma Therapeutics Holdings, Inc. (a)
|
20,460
|
116,417
|
|
Fusion Pharmaceuticals, Inc. (a)
|
1,740,302
|
6,247,684
|
|
G1 Therapeutics, Inc. (a)(b)
|
487,104
|
2,367,325
|
|
Galapagos NV sponsored ADR (a)
|
53,343
|
2,934,398
|
|
Generation Bio Co. (a)
|
137,100
|
770,502
|
|
Geron Corp. (a)
|
189,606
|
261,656
|
|
Geron Corp. warrants 12/31/25 (a)
|
2,100,000
|
603,350
|
|
Gilead Sciences, Inc.
|
1,048,087
|
67,968,442
|
|
Global Blood Therapeutics, Inc. (a)
|
189,216
|
4,719,047
|
|
Graphite Bio, Inc.
|
1,312,653
|
3,084,735
|
|
Gritstone Bio, Inc. (a)(b)
|
469,480
|
948,350
|
|
Halozyme Therapeutics, Inc. (a)
|
659,100
|
30,305,418
|
|
Homology Medicines, Inc. (a)(b)
|
651,341
|
957,471
|
|
Hookipa Pharma, Inc. (a)(b)
|
2,256,500
|
3,881,180
|
|
Horizon Therapeutics PLC (a)
|
1,366,353
|
122,548,201
|
|
Icosavax, Inc. (a)
|
562,657
|
3,820,441
|
|
Ideaya Biosciences, Inc. (a)(b)
|
825,274
|
9,201,805
|
|
Idorsia Ltd. (a)(b)
|
1,371,271
|
22,730,618
|
|
Imago BioSciences, Inc.
|
284,600
|
4,599,136
|
|
Immuneering Corp. (b)
|
222,971
|
998,910
|
|
Immunic, Inc. (a)(b)
|
509,372
|
3,158,106
|
|
Immunocore Holdings PLC ADR (a)
|
86,365
|
2,448,448
|
|
ImmunoGen, Inc. (a)
|
804,623
|
2,944,920
|
|
Incyte Corp. (a)
|
275,500
|
20,907,695
|
|
Inhibikase Therapeutics, Inc. (a)(b)
|
433,300
|
396,816
|
|
Inhibrx, Inc. (a)
|
21,600
|
282,312
|
|
Inozyme Pharma, Inc. (a)(b)
|
609,380
|
2,248,612
|
|
Insmed, Inc. (a)
|
266,820
|
5,021,552
|
|
Instil Bio, Inc. (a)
|
1,445,074
|
8,677,669
|
|
Intellia Therapeutics, Inc. (a)
|
885,001
|
40,833,946
|
|
Ionis Pharmaceuticals, Inc. (a)
|
1,246,677
|
45,528,644
|
|
Iovance Biotherapeutics, Inc. (a)
|
566,079
|
3,821,033
|
|
iTeos Therapeutics, Inc. (a)
|
69,881
|
1,222,918
|
|
Iveric Bio, Inc. (a)
|
451,988
|
4,718,755
|
|
Janux Therapeutics, Inc. (b)
|
515,742
|
5,740,208
|
|
Jounce Therapeutics, Inc. (a)
|
1,080,839
|
4,182,847
|
|
Karuna Therapeutics, Inc. (a)
|
229,311
|
23,921,724
|
|
Keros Therapeutics, Inc. (a)
|
378,977
|
12,809,423
|
|
Kiniksa Pharmaceuticals Ltd. (a)(b)
|
192,666
|
1,475,822
|
|
Kinnate Biopharma, Inc. (a)(b)
|
1,009,816
|
8,017,939
|
|
Kronos Bio, Inc. (a)(b)
|
744,460
|
2,769,391
|
|
Krystal Biotech, Inc. (a)(b)(c)
|
2,105,960
|
123,998,925
|
|
Kymera Therapeutics, Inc. (a)(b)
|
339,354
|
4,842,582
|
|
Legend Biotech Corp. ADR (a)(b)
|
1,207,675
|
51,072,576
|
|
Lyell Immunopharma, Inc. (b)
|
362,253
|
1,499,727
|
|
Macrogenics, Inc. (a)(b)
|
364,316
|
1,264,177
|
|
Madrigal Pharmaceuticals, Inc. (a)(b)
|
153,140
|
10,166,965
|
|
MannKind Corp. (a)(b)
|
6,582,901
|
27,516,526
|
|
Merus BV (a)(b)
|
630,486
|
11,701,820
|
|
Minerva Neurosciences, Inc. (a)
|
226,179
|
90,472
|
|
Mirati Therapeutics, Inc. (a)
|
326,848
|
12,799,368
|
|
Moderna, Inc. (a)
|
255,093
|
37,072,666
|
|
Monte Rosa Therapeutics, Inc. (b)
|
1,451,205
|
11,232,327
|
|
Morphic Holding, Inc. (a)
|
805,337
|
18,877,099
|
|
Morphosys AG sponsored ADR (a)(b)
|
131,228
|
736,189
|
|
Natera, Inc. (a)
|
323,010
|
11,851,237
|
|
Neximmune, Inc. (a)(b)
|
525,000
|
1,197,000
|
|
Nkarta, Inc. (a)(b)
|
879,766
|
12,695,023
|
|
Nurix Therapeutics, Inc. (a)(b)
|
1,735,163
|
17,507,795
|
|
Nuvalent, Inc. Class A (a)(b)
|
204,174
|
1,808,982
|
|
Omega Therapeutics, Inc. (a)
|
915,541
|
2,078,278
|
|
Oragenics, Inc. (a)(e)
|
155,806
|
50,637
|
|
ORIC Pharmaceuticals, Inc. (a)
|
425,446
|
1,420,990
|
|
PMV Pharmaceuticals, Inc. (a)(b)
|
772,700
|
9,086,952
|
|
Poseida Therapeutics, Inc. (a)
|
483,183
|
1,096,825
|
|
Praxis Precision Medicines, Inc. (a)(b)
|
982,929
|
8,158,311
|
|
Prelude Therapeutics, Inc. (a)
|
359,156
|
1,508,455
|
|
Prometheus Biosciences, Inc. (a)(b)
|
242,300
|
6,314,338
|
|
Protagonist Therapeutics, Inc. (a)
|
1,226,378
|
10,743,071
|
|
Prothena Corp. PLC (a)
|
852,589
|
23,215,998
|
|
PTC Therapeutics, Inc. (a)
|
2,267,944
|
66,609,515
|
|
Rallybio Corp. (a)(b)
|
1,199,143
|
16,308,345
|
|
RAPT Therapeutics, Inc. (a)
|
1,113,177
|
16,385,965
|
|
Recursion Pharmaceuticals, Inc. (a)(b)
|
89,200
|
545,904
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
204,654
|
136,041,700
|
|
Relay Therapeutics, Inc. (a)(b)
|
1,511,389
|
24,605,413
|
|
Repare Therapeutics, Inc. (a)
|
615,260
|
5,648,087
|
|
Replimune Group, Inc. (a)(b)
|
1,080,217
|
15,695,553
|
|
Revolution Medicines, Inc. (a)(b)
|
51,992
|
882,824
|
|
Rhythm Pharmaceuticals, Inc. (a)(b)
|
553,411
|
1,903,734
|
|
Rocket Pharmaceuticals, Inc. (a)(b)
|
223,736
|
2,651,272
|
|
Rubius Therapeutics, Inc. (a)(b)
|
595,229
|
654,752
|
|
Sage Therapeutics, Inc. (a)
|
321,935
|
10,066,907
|
|
Sana Biotechnology, Inc. (a)(b)
|
27,690
|
142,050
|
|
Sarepta Therapeutics, Inc. (a)
|
560,004
|
40,779,491
|
|
Scholar Rock Holding Corp. (a)
|
1,543,247
|
7,747,100
|
|
Seagen, Inc. (a)
|
970,874
|
131,728,184
|
|
Selecta Biosciences, Inc. (a)(b)
|
1,032,715
|
911,061
|
|
Sensorion SA (a)
|
2,738,352
|
1,206,771
|
|
Seres Therapeutics, Inc. (a)(b)
|
687,847
|
2,132,326
|
|
Shattuck Labs, Inc. (a)
|
110,936
|
317,277
|
|
Silverback Therapeutics, Inc. (a)
|
14,266
|
49,788
|
|
Springworks Therapeutics, Inc. (a)(b)
|
443,611
|
8,401,992
|
|
Stoke Therapeutics, Inc. (a)(b)
|
526,536
|
6,376,351
|
|
Surface Oncology, Inc. (a)(b)
|
144,645
|
267,593
|
|
Surrozen, Inc. (a)(b)
|
252,900
|
627,192
|
|
Sutro Biopharma, Inc. (a)
|
663,300
|
2,885,355
|
|
Syndax Pharmaceuticals, Inc. (a)(b)
|
124,200
|
2,049,300
|
|
Syros Pharmaceuticals, Inc. (a)(b)
|
1,045,057
|
858,619
|
|
Syros Pharmaceuticals, Inc. warrants 10/10/22 (a)
|
21,625
|
0
|
|
Tango Therapeutics, Inc. (a)
|
927,488
|
6,204,895
|
|
Taysha Gene Therapies, Inc. (a)(b)
|
882,847
|
2,251,260
|
|
Tenaya Therapeutics, Inc. (a)
|
1,263,918
|
8,468,251
|
|
TG Therapeutics, Inc. (a)(b)
|
2,066,920
|
9,135,786
|
|
Travere Therapeutics, Inc. (a)
|
372,928
|
8,692,952
|
|
Turning Point Therapeutics, Inc. (a)
|
451,601
|
15,973,127
|
|
Twist Bioscience Corp. (a)(b)
|
979,432
|
33,339,865
|
|
Tyra Biosciences, Inc. (b)
|
553,401
|
3,779,729
|
|
Ultragenyx Pharmaceutical, Inc. (a)
|
978,351
|
45,884,662
|
|
uniQure B.V. (a)
|
255,608
|
3,670,531
|
|
United Therapeutics Corp. (a)
|
429,609
|
98,956,137
|
|
Vaxcyte, Inc. (a)
|
580,989
|
13,937,926
|
|
Vera Therapeutics, Inc. (a)
|
779,768
|
11,337,827
|
|
Vertex Pharmaceuticals, Inc. (a)
|
1,076,375
|
289,168,144
|
|
Verve Therapeutics, Inc. (b)
|
372,567
|
5,648,116
|
|
Vor Biopharma, Inc. (a)(b)
|
696,659
|
2,932,934
|
|
Werewolf Therapeutics, Inc. (a)(b)
|
518,530
|
1,965,229
|
|
X4 Pharmaceuticals, Inc. warrants 4/12/24 (a)
|
450,000
|
92
|
|
Xencor, Inc. (a)
|
355,343
|
7,934,809
|
|
Xenon Pharmaceuticals, Inc. (a)
|
819,269
|
21,587,738
|
|
Xilio Therapeutics, Inc.
|
612,462
|
1,837,386
|
|
Y-mAbs Therapeutics, Inc. (a)(b)
|
1,969,051
|
24,494,994
|
|
Yumanity Therapeutics, Inc. (a)
|
260,182
|
278,395
|
|
Zentalis Pharmaceuticals, Inc. (a)
|
638,433
|
15,392,620
|
|
3,988,884,327
|
|||
Chemicals - 0.0%
|
|||
Specialty Chemicals - 0.0%
|
|||
Ginkgo Bioworks Holdings, Inc. Class A (a)(b)
|
358,700
|
1,104,796
|
|
Food & Staples Retailing - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (a)(e)
|
2,777
|
4,749
|
|
Health Care Equipment & Supplies - 0.1%
|
|||
Health Care Equipment - 0.1%
|
|||
Alpha Tau Medical Ltd. Class A (a)(b)
|
308,578
|
2,388,394
|
|
Novocure Ltd. (a)
|
11,113
|
893,263
|
|
3,281,657
|
|||
Health Care Supplies - 0.0%
|
|||
Pulmonx Corp. (a)(b)
|
8,300
|
151,558
|
|
TOTAL HEALTH CARE EQUIPMENT & SUPPLIES
|
3,433,215
|
||
Health Care Providers & Services - 0.4%
|
|||
Health Care Services - 0.4%
|
|||
23andMe Holding Co. Class B (f)
|
3,206,519
|
9,619,557
|
|
Guardant Health, Inc. (a)
|
140,200
|
5,745,396
|
|
Precipio, Inc. (a)(b)
|
525
|
599
|
|
15,365,552
|
|||
Health Care Technology - 0.2%
|
|||
Health Care Technology - 0.2%
|
|||
Schrodinger, Inc. (a)
|
407,327
|
10,525,330
|
|
Life Sciences Tools & Services - 0.6%
|
|||
Life Sciences Tools & Services - 0.6%
|
|||
10X Genomics, Inc. (a)
|
15,719
|
804,656
|
|
Absci Corp. (b)
|
997,900
|
3,642,335
|
|
Evotec OAI AG (a)
|
200,700
|
5,558,906
|
|
Maravai LifeSciences Holdings, Inc. (a)
|
107,700
|
3,354,855
|
|
Olink Holding AB ADR (a)
|
57,100
|
671,496
|
|
Pacific Biosciences of California, Inc. (a)(b)
|
827,912
|
4,661,145
|
|
Quanterix Corp. (a)
|
188,322
|
3,175,109
|
|
Seer, Inc. (a)
|
304,058
|
2,700,035
|
|
24,568,537
|
|||
Pharmaceuticals - 7.6%
|
|||
Pharmaceuticals - 7.6%
|
|||
Aclaris Therapeutics, Inc. (a)
|
435,589
|
5,571,183
|
|
Adimab LLC (a)(d)(e)(g)
|
1,954,526
|
80,645,502
|
|
Aerie Pharmaceuticals, Inc. (a)
|
526,000
|
2,724,680
|
|
Afferent Pharmaceuticals, Inc. rights 12/31/24 (a)(d)
|
8,274,568
|
7,778,094
|
|
Antengene Corp. (a)(f)
|
318,671
|
289,952
|
|
Aradigm Corp. (a)(d)
|
148,009
|
6,808
|
|
Aradigm Corp. (a)(d)
|
11,945
|
549
|
|
Arvinas Holding Co. LLC (a)
|
1,119,419
|
46,668,578
|
|
Atea Pharmaceuticals, Inc. (a)
|
66,800
|
526,384
|
|
Axsome Therapeutics, Inc. (a)(b)
|
117,302
|
2,932,550
|
|
Chiasma, Inc. warrants 12/16/24 (a)(d)
|
382,683
|
4
|
|
CinCor Pharma, Inc.
|
85,193
|
1,325,603
|
|
DICE Therapeutics, Inc.
|
356,600
|
4,903,250
|
|
Edgewise Therapeutics, Inc. (a)
|
724,054
|
4,525,338
|
|
Fulcrum Therapeutics, Inc. (a)
|
1,144,976
|
8,152,229
|
|
GH Research PLC (b)
|
1,388,224
|
13,910,004
|
|
Harmony Biosciences Holdings, Inc. (a)
|
182,500
|
7,957,000
|
|
Ikena Oncology, Inc. (a)
|
553,247
|
2,157,663
|
|
Intra-Cellular Therapies, Inc. (a)
|
627,976
|
36,045,822
|
|
Kaleido Biosciences, Inc. (a)(b)
|
84,860
|
7,065
|
|
Longboard Pharmaceuticals, Inc. (a)
|
371,100
|
1,840,656
|
|
Marinus Pharmaceuticals, Inc. (a)(b)
|
249,965
|
1,212,330
|
|
NGM Biopharmaceuticals, Inc. (a)
|
183,700
|
2,542,408
|
|
Nuvation Bio, Inc. (a)(b)
|
1,483,691
|
5,237,429
|
|
OptiNose, Inc. (a)(b)
|
702,319
|
1,443,266
|
|
Pharvaris BV (a)
|
461,407
|
8,176,132
|
|
Pliant Therapeutics, Inc. (a)
|
971,031
|
5,466,905
|
|
Rain Therapeutics, Inc. (a)(b)
|
255,887
|
593,658
|
|
Reata Pharmaceuticals, Inc. (a)(b)
|
529,063
|
14,961,902
|
|
Roivant Sciences Ltd. (e)
|
2,500,000
|
11,100,000
|
|
Royalty Pharma PLC
|
442,620
|
18,209,387
|
|
Terns Pharmaceuticals, Inc. (a)
|
101,009
|
174,746
|
|
Theseus Pharmaceuticals, Inc.
|
1,645,528
|
11,107,314
|
|
Trevi Therapeutics, Inc. (a)(b)
|
83,225
|
201,405
|
|
Tricida, Inc. (a)(b)
|
178,300
|
1,487,022
|
|
UCB SA
|
227,977
|
20,108,225
|
|
Ventyx Biosciences, Inc. (b)
|
754,161
|
13,205,359
|
|
Verrica Pharmaceuticals, Inc. (a)(b)
|
645,496
|
1,245,807
|
|
WAVE Life Sciences (a)
|
159,660
|
223,524
|
|
344,665,733
|
|||
|
TOTAL COMMON STOCKS
(Cost $4,508,719,587)
|
4,388,552,239
|
||
Convertible Preferred Stocks - 1.6%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 1.4%
|
|||
Biotechnology - 1.4%
|
|||
ElevateBio LLC Series C (a)(d)(e)
|
216,600
|
990,512
|
|
Korro Bio, Inc.:
|
|||
Series B1 (d)(e)
|
957,854
|
1,465,517
|
|
Series B2 (d)(e)
|
899,280
|
1,375,898
|
|
National Resilience, Inc. Series B (a)(d)(e)
|
732,064
|
44,509,491
|
|
SalioGen Therapeutics, Inc. Series B (d)(e)
|
94,461
|
5,651,602
|
|
ValenzaBio, Inc. Series A (a)(d)(e)
|
1,685,311
|
8,291,730
|
|
62,284,750
|
|||
Health Care Providers & Services - 0.0%
|
|||
Health Care Services - 0.0%
|
|||
Scorpion Therapeutics, Inc. Series B (a)(d)(e)
|
3,099,905
|
3,130,904
|
|
Pharmaceuticals - 0.2%
|
|||
Pharmaceuticals - 0.2%
|
|||
Afferent Pharmaceuticals, Inc. Series C (a)(d)(e)
|
8,274,568
|
83
|
|
Aristea Therapeutics, Inc. Series B (a)(d)(e)
|
836,400
|
7,979,256
|
|
7,979,339
|
|||
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $53,020,299)
|
73,394,993
|
||
Money Market Funds - 11.9%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 0.82% (h)
|
62,647,630
|
62,660,159
|
|
Fidelity Securities Lending Cash Central Fund 0.82% (h)(i)
|
475,644,438
|
475,692,003
|
|
|
TOTAL MONEY MARKET FUNDS
(Cost $538,318,521)
|
538,352,162
|
||
|
TOTAL INVESTMENT IN SECURITIES - 110.6%
(Cost $5,100,058,407)
|
5,000,299,394
|
NET OTHER ASSETS (LIABILITIES) - (10.6)%
|
(477,962,570)
|
NET ASSETS - 100.0%
|
4,522,336,824
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Affiliated company
|
(d)
|
Level 3 security
|
(e)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $165,254,909 or 3.7% of net assets.
|
(f)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $9,909,509 or 0.2% of net assets.
|
(g)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Adimab LLC
|
9/17/14 - 6/05/15
|
31,218,836
|
Afferent Pharmaceuticals, Inc. Series C
|
7/01/15
|
0
|
Aristea Therapeutics, Inc. Series B
|
10/06/20
|
4,611,659
|
Cyclerion Therapeutics, Inc.
|
4/02/19
|
1,404,026
|
ElevateBio LLC Series C
|
3/09/21
|
908,637
|
Korro Bio, Inc. Series B1
|
12/17/21
|
2,499,999
|
Korro Bio, Inc. Series B2
|
12/17/21
|
2,499,998
|
MedAvail Holdings, Inc.
|
7/02/12
|
416,675
|
National Resilience, Inc. Series B
|
12/01/20
|
9,999,994
|
Oragenics, Inc.
|
7/31/12 - 6/21/18
|
2,337,087
|
Roivant Sciences Ltd.
|
5/01/21
|
25,000,000
|
SalioGen Therapeutics, Inc. Series B
|
12/10/21
|
10,000,019
|
Scorpion Therapeutics, Inc. Series B
|
1/08/21
|
7,500,000
|
ValenzaBio, Inc. Series A
|
3/25/21
|
14,999,993
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
%ownership,
end
of period
|
Fidelity Cash Central Fund 0.82%
|
42,446,755
|
378,366,714
|
358,153,310
|
74,267
|
3,258
|
(3,258)
|
62,660,159
|
0.1%
|
Fidelity Securities Lending Cash Central Fund 0.82%
|
492,109,261
|
696,466,995
|
712,884,253
|
1,792,284
|
-
|
-
|
475,692,003
|
1.3%
|
Total
|
534,556,016
|
1,074,833,709
|
1,071,037,563
|
1,866,551
|
3,258
|
(3,258)
|
538,352,162
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Adverum Biotechnologies, Inc.
|
-
|
14,311,389
|
-
|
-
|
-
|
(4,803,432)
|
9,507,957
|
Candel Therapeutics, Inc.
|
8,593,545
|
-
|
5,817,649
|
-
|
(3,654,447)
|
4,278,337
|
-
|
Krystal Biotech, Inc.
|
126,760,516
|
6,531,325
|
-
|
-
|
-
|
(9,292,916)
|
123,998,925
|
Total
|
135,354,061
|
20,842,714
|
5,817,649
|
-
|
(3,654,447)
|
(9,818,011)
|
133,506,882
|